Ferring study shows benefits of individualised Rekovelle dosing regimen

Ferring Pharmaceuticals has reported the findings of a new analysis of Rekovelle, showing the benefits it can offer when used as a personalised medicine for fertility patients.

Data from the ESTHER-1 and ESTHER-2 phase III clinical trials have indicated that cumulative live birth rates were similar among women receiving the follitropin delta therapy Rekovelle and those given conventional follitropin alfa treatment.

In addition, Rekovelle demonstrated a favourable safety profile in women with high anti-Mullerian hormone (AMH) levels, with the prevalence of early ovarian hyperstimulation syndrome shown to be lower among those receiving the Ferring therapy.

These results were presented at the recent annual meeting of the European Society of Human Reproduction and Embryology, and offer further evidence that providing individualised treatment for patients with different characteristics could prove beneficial.

Per Falk, executive vice-president and chief scientific officer at Ferring Pharmaceuticals, said: "Rekovelle's individualised dosing regimen, based on a patient's AMH level and body weight, provides clinicians with a consistent, evidence-based approach to personalising treatment for their patients."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.